Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Lymphoma
Phase 2 epcoritamab CD20×CD3 bispecific antibody plus R-CHOP in newly diagnosed aggressive B-cell NHL
This Phase 2, open-label, two-arm, sequential-assignment study tests epcoritamab (a subcutaneous CD20×CD3 T-cell–engaging bispecific antibody) combined with R-CHOP in newly diagnosed, CD20+ aggressive B-cell…
NCT07588698 Exploratory - New trial Spotlight
Chronic lymphocytic leukemia
Phase 3 rocbrutinib (LP-168) dual covalent/reversible BTK inhibitor vs pirtobrutinib non-covalent BTK inhibitor.
Newave Pharmaceutical is running this Phase 3, randomized, open-label, global multicenter trial in relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, enrolling ~306 adults and randomizing 1:1 to…
NCT07342478 Registrational - New trial
Chronic lymphocytic leukemia
Phase 2 AVT triplet: tafasitamab (CD19 mAb) + acalabrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor)
This Phase 2, open-label study at City of Hope tests whether adding tafasitamab (a CD19-directed monoclonal antibody marketed as Monjuvi by Incyte and MorphoSys/Novartis) to the acalabrutinib + venetoclax backbone…
NCT07582159 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 1 BSB-2002 mutant NPM1–targeted TCR-T therapy in relapsed/refractory AML
This Phase 1, open-label, dose-finding study evaluates BSB-2002, a personalized autologous T cell receptor–engineered T cell (TCR‑T) therapy whose introduced TCR recognizes a mutant NPM1 peptide presented by…
NCT07583303 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1 ASTX727 (oral decitabine + cedazuridine; DNA hypomethylating agent + cytidine deaminase inhibitor) with filgrastim (G‑CSF)
This Phase 1, post–allogeneic hematopoietic cell transplant (HCT) maintenance study tests whether ASTX727 plus filgrastim can be given safely, and at what dose, to help prevent relapse in children with high-risk AML…
NCT07012044 Exploratory - New trial
Acute lymphoblastic leukemia
Phase 1 4A10 (ALT-101) tests anti-CD127 (IL-7Rα) blocking antibody in R/R ALL/LL.
Allterum Therapeutics’ first-in-human, open-label Phase 1 study evaluates 4A10, an IgG1 monoclonal antibody that binds CD127 (the IL‑7 receptor alpha chain) to block IL‑7 survival signaling and promote…
NCT07586618 First-in-human - New trial
Other blood cancers and transplant
Phase 2 cord blood transplantation (allogeneic hematopoietic stem-cell graft) after myeloablative conditioning in pediatric/AYA blood cancers
This Memorial Sloan Kettering Cancer Center, multi-cohort Phase 2 study tests whether umbilical cord blood transplantation (CBT)—used as a first allogeneic transplant in high-risk remission patients or as a second…
NCT07566377 Exploratory - New trial
Other blood cancers and transplant
Phase 2 TMLI conditioning + fludarabine/melphalan; IMRT marrow/lymphoid targeting + DNA-damaging chemo
City of Hope Medical Center is running this Phase 2 study testing whether total marrow and lymphoid irradiation (TMLI)—an intensity-modulated radiation approach that concentrates dose to marrow, lymph node chains,…
NCT07582172 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1 RLY-8161 trial tests an NRAS-selective small-molecule inhibitor (NRAS target)
This Phase 1 first-in-human, open-label, multicenter study evaluates RLY-8161—an NRAS-selective small-molecule inhibitor—from Relay Therapeutics in adults with unresectable Stage III/IV NRAS-mutant melanoma or other…
NCT07584226 First-in-human - New trial
Multiple solid tumors
Phase 1 Yttrium-90 (beta-emitting glass microspheres) radioembolization dose-escalation in unresectable liver tumors
Northwestern University’s MARGIN Study is a prospective, non-randomized, open-label dose-escalation trial designed to define an “ablative” absorbed-dose range for yttrium-90 (Y-90) transarterial radioembolization…
NCT07586046 Exploratory - New trial
Multiple solid tumors
Phase 1/2a PMC2129G12 intratumoral mRNA-LNP encodes EpCAM×CD3 bispecific + cytokines
This Phase 1/2a, open-label, single-arm study from IntraAb evaluates intratumoral PMC2129G12, an mRNA–lipid nanoparticle designed to drive localized, transient tumor expression of a humanized EpCAM-targeted,…
NCT07587879 First-in-human - New trial
Multiple solid tumors
Phase 1/2 DT-7012 anti-CCR8 monoclonal antibody (Treg-depleting immunotherapy) in solid tumors.
This first-in-human, multicenter, open-label Phase 1/2 study (DOMISOL; DT-7012-CLI-001) evaluates DT-7012, a CCR8-targeting monoclonal antibody designed to deplete CCR8+ intratumoral regulatory T cells (Tregs) and…
NCT06819735 First-in-human - Trial result
Breast cancer
ARTEMIS (AC neoadjuvant chemo) links “immune hot/cold” contexture to pCR in early TNBC
ARTEMIS (NCT02276443) tested whether adding a gene-expression molecular classifier could better select early-stage triple-negative breast cancer (TNBC) patients for neoadjuvant doxorubicin/cyclophosphamide (AC)…
NCT02276443 - Trial result
Prostate cancer
PSMA PET/CT-guided sRT + field/ADT tailoring delivers 97% 5-year OS after post-RP recurrence
PSMA PET/CT is a prostate cancer–specific molecular imaging modality targeting PSMA to localize recurrence and guide salvage radiotherapy (sRT) after radical prostatectomy. In this retrospective analysis of 5…
- Trial result
Multiple myeloma
Daratumumab (CD38) + ixazomib (oral proteasome inhibitor) sans dexamethasone delivers 19.5-mo PFS in frail elderly RRMM
Daratumumab is an anti-CD38 monoclonal antibody and ixazomib is an oral proteasome inhibitor; IFM 2018-02 (NCT03757221) tested this dexamethasone-free doublet (with methylprednisolone premedication) in a prospective…
NCT03757221 - Trial result
Non-small cell lung cancer
Amivantamab (EGFR–MET bispecific) delivers 32% ORR in METex14 NSCLC—including 19% post–MET TKI
Amivantamab is an intravenous EGFR–MET bispecific antibody with immune cell–directing activity evaluated in the CHRYSALIS trial in advanced MET exon 14 skipping (METex14) NSCLC after progression on or refusal of…
- Trial result
Non-small cell lung cancer
Lazertinib (3rd-gen EGFR TKI) matches osimertinib in 1L EGFR-mutant NSCLC—no PFS advantage in MARIPOSA
Lazertinib is a CNS-penetrant, third-generation EGFR tyrosine kinase inhibitor (TKI) engineered for mutant EGFR selectivity (and chosen for combination with the EGFR-MET bispecific antibody amivantamab partly due to…
- Trial result
Non-small cell lung cancer
Cemiplimab (PD-1) monotherapy doubles OS vs chemo in PD-L1≥50% 1L NSCLC at 5 years
Cemiplimab is an anti–PD-1 checkpoint inhibitor given as monotherapy for up to 2 years; EMPOWER-Lung 1 was a randomized Phase 3 trial comparing cemiplimab 350mg IV Q3W vs investigator’s-choice platinum-doublet…
- Trial result Spotlight
Head and neck cancer
BCA101 (EGFR/TGF‑β bifunctional antibody) + pembrolizumab drives 54% ORR in 1L HPV− R/M HNSCC
Ficerafusp alfa (BCA101) is a bifunctional EGFR-targeting antibody fused to a TGF‑β “trap,” designed to counter EGFR-driven signaling and TGF‑β–mediated immune exclusion; it was combined with pembrolizumab…
NCT04429542 - Trial result Spotlight
Head and neck cancer
Trastuzumab deruxtecan (HER2 ADC) drives 67% RECIST responses in HER2-low/HER2-mutant salivary/lacrimal cancers
Trastuzumab deruxtecan (T-DXd; DS-8201), a HER2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload, was given to patients with recurrent/metastatic secretory gland cancers of the head and…
- Trial result
Head and neck cancer
ReACT 1.0 HPV ctDNA (TTMV-HPV DNA) response-adaptive de-escalation delivers 93% 2-year PFS in HPV+ OPC
LBx-guided risk-adapted therapy: ReACT 1.0 (exploratory Phase II; NCT04900623) enrolled 102 patients with HPV-positive oropharyngeal carcinoma and used on-treatment HPV circulating tumor DNA (ctDNA) kinetics to…
NCT04900623 - Trial result Spotlight
Skin cancer (non-melanoma)
ALA-PDT (20% aminolevulinic acid + blue light) Delivers 100% Histologic Clearance in Facial cSCC in situ
In the single-center, investigator-initiated, open-label NCT06159842 study, patients with biopsy-confirmed facial cutaneous squamous cell carcinoma in situ (cSCCis/Bowen disease) received 2 cycles of 20%…
NCT06159842 - Trial result Spotlight
Pancreatic cancer
Daraxonrasib (RMC-6236) RAS(ON) multiselective inhibitor delivers 35% ORR in 2L RAS G12 PDAC
Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that binds GTP-bound mutant and wild-type RAS, evaluated in the Phase 1/2 RMC-6236-001 study (NCT05379985) in previously treated RAS-mutated PDAC.…
NCT05379985 - Trial result Spotlight
Stomach and esophageal cancer
Zolbetuximab (anti-CLDN18.2 mAb) + chemo extends PFS to 20.5 months in Japanese 1L gastric/GEJ cancer
Zolbetuximab is a monoclonal antibody targeting CLDN18.2 and is combined here with platinum/fluoropyrimidine chemotherapy as first-line therapy for CLDN18.2-positive (typically defined in SPOTLIGHT/GLOW as ≥75% tumor…
NCT03504397 - New trial
Prostate cancer
Phase 2/3 prostate SBRT trial tests focal DIL boost vs whole-gland boost (ionizing radiation)
This Phase 2/3 randomized study from the University of Nebraska compares two linear-accelerator–based stereotactic body radiotherapy (SBRT) dose-escalation strategies for treatment‑naïve localized prostate cancer.…
NCT07574489 Exploratory - New trial
Prostate cancer
Phase 2 TriAdeno (PSA/MUC1/brachyury Ad5 vaccine) + N-803 IL-15 superagonist in localized prostate cancer
This Phase 2 National Cancer Institute trial tests whether TriAdeno—an adenovirus type 5 (Ad5)–based therapeutic cancer vaccine expressing three tumor antigens (PSA, MUC1, and brachyury) to drive antigen-specific…
NCT07574541 Exploratory - New trial
Prostate cancer
Phase 1 INR731 trial tests oral investigational agent in mCRPC.
*No disclosed MOA. We do not include details of trials without this basic information.*
NCT07570979 First-in-human - New trial Spotlight
Kidney cancer
Phase 1 LNK001 dual ENPP3/CAIX AND-gated CAR T in ccRCC
MD Anderson Cancer Center is running a Phase 1, two-part (dose escalation then expansion) study testing LNK001, an autologous CAR T-cell therapy engineered as an AND-gate that requires dual recognition of ENPP3 and…
NCT07564232 First-in-human - New trial
Lymphoma
Phase 2 emapalumab IFN-γ–neutralizing antibody to prevent BsAb CRS/ICANS in R/R MM, LBCL
This Phase 2, single-arm prophylaxis study tests whether emapalumab (Gamifant)—an interferon-gamma (IFN-γ)–blocking monoclonal antibody—can reduce cytokine release syndrome (CRS) and/or immune effector…
NCT07567014 Exploratory - New trial
Stomach and esophageal cancer
Phase 2 rinatabart sesutecan (Rina‑S) FRα-targeted antibody–drug conjugate with exatecan (topoisomerase I inhibitor)
Genmab’s Phase 2, open-label, multicohort study evaluates Rina‑S monotherapy in advanced/metastatic, progressive, unresectable gastrointestinal cancers after prior standard therapies, enrolling up to ~160…
NCT07539311 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.